Towards Healthcare
Antimalarial Drugs Market to Reach USD 1.67 Bn by 2034

Antimalarial Drugs Market Insights Highlighting Combination Therapies and Vaccines

According to market projections, the antimalarial drugs sector is expected to grow from USD 1.07 billion in 2024 to USD 1.67 billion by 2034, reflecting a CAGR of 4.57%. Establishing awareness and government programs are propelling the global market development. In 2024, Africa led the market due to the growing cases and deaths of malaria.

  • Insight Code: 6044
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The antimalarial drugs market in 2025 is valued at USD 1.12 billion and is projected to climb to USD 1.67 billion by 2034, with a CAGR of 4.57% over the forecast period.

Africa is currently leading the antimalarial drugs market share 55% due to a huge burden of malaria cases and deaths are boosting demand for novel and effective antimalarial approaches, including drugs.

Some key players include Novartis AG, Sanofi, Cipla Ltd., Ipca Laboratories Ltd., and GlaxoSmithKline.

Key trends include the broader demand for antimalarial vaccines, growth in awareness programs, and innovations in combination therapies and ACTs.

The side effects of antimalarial drugs are gastrointestinal issues, headache, blurred vision, insomnia, and neuropsychiatric issues. 

WHO, CDC, NIH, US FDA, NCVBDC, NHM, MedlinePlus.gov, defence.gov